Femasys (NASDAQ:FEMY) Given “Sell (E+)” Rating at Weiss Ratings

Femasys (NASDAQ:FEMY)‘s stock had its “sell (e+)” rating restated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other analysts also recently commented on the company. HC Wainwright decreased their price target on Femasys from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Wall Street Zen raised Femasys to a “sell” rating in a research report on Saturday, October 4th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Femasys Stock Performance

Shares of FEMY opened at $0.60 on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.41 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $19.45 million, a price-to-earnings ratio of -0.69 and a beta of -2.64. The stock has a 50 day moving average of $0.53 and a 200 day moving average of $0.87. Femasys has a 12 month low of $0.31 and a 12 month high of $1.80.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.80 million. Femasys had a negative return on equity of 713.74% and a negative net margin of 1,113.72%. As a group, sell-side analysts forecast that Femasys will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Femasys

Several institutional investors and hedge funds have recently bought and sold shares of FEMY. Citadel Advisors LLC bought a new position in Femasys during the fourth quarter valued at $45,000. Clear Creek Financial Management LLC grew its holdings in Femasys by 5.5% during the first quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock valued at $338,000 after purchasing an additional 14,000 shares during the period. Dauntless Investment Group LLC bought a new position in shares of Femasys in the first quarter worth $1,969,000. Jane Street Group LLC bought a new position in shares of Femasys in the second quarter worth $82,000. Finally, Osaic Holdings Inc. bought a new position in shares of Femasys in the second quarter worth $45,000. 65.27% of the stock is owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.